Zydus Cadila to acquire two ANDAs from Teva Pharmaceutical Industries – Feedback

Drug maker Cadila Healthcare Ltd, also known as Zydus Cadila, has acquired two abbreviated new drug applications (ANDA) from Teva Pharmaceutical Industries Ltd that are being divested by the Israel-based company as a precondition to its acquisition of Allergan Plc.’s generic business.

“The acquisition of these ANDAs is contingent on the closing of the Teva-Allergan generics transaction and approval by the US Federal Trade Commission (FTC),” Zydus said in a statement to the stock exchanges on Monday. The financial details of the transaction were not disclosed. The company said the two ANDAs have been acquired by its subsidiary Zydus Worldwide DMCC and that the transaction will be financed through the group’s internal accruals. The acquired portfolio comprises an already-commercialized ANDA and one pipeline ANDA, which is a transdermal patch. The estimated market size of the two ANDAs put together is nearly $200 million, Zydus said.


About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *